Kuroda, Junya <br/><br/>
The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate.  [electronic resource] 

 -  Blood  Sep 2003 
 - 2229-35 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0006-4971 
<br/><br/><label>Standard No.: </label>10.1182/blood-2003-01-0305  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>ATP Binding Cassette Transporter, Subfamily B, Member 1--metabolism<br/>Animals<br/>Antineoplastic Agents--pharmacology<br/>Apoptosis--drug effects<br/>Benzamides<br/>Cell Division--drug effects<br/>Diphosphonates--pharmacology<br/>Drug Synergism<br/>HL-60 Cells<br/>Hematopoietic Stem Cells--cytology<br/>Humans<br/>Imatinib Mesylate<br/>Imidazoles--pharmacology<br/>K562 Cells<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy<br/>Mice<br/>Mice, Inbred NOD<br/>Mice, SCID<br/>Monomeric GTP-Binding Proteins--metabolism<br/>Pamidronate<br/>Piperazines--pharmacology<br/>Protein Prenylation<br/>Pyrimidines--pharmacology<br/>Zoledronic Acid